Zone center phonons of the orthorhombic RMnO3 (R = Pr, Eu, Tb, Dy, Ho) perovskites

A short range force constant model (SRFCM) has been applied for the first time to investigate the phonons in RMnO3 (R = Pr, Eu, Tb, Dy, Ho) perovskites in their orthorhombic phase. The calculations with 17 stretching and bending force constants provide good agreement for the observed Raman frequencies. The infrared frequencies have been assigned for the first time. PACS Codes: 36.20.Ng, 33.20.Fb, 34.20.CfComment: 8 pages, 1 figur

Synthesis and analysis of abnormal wurtzite ZnSe nanowheels

An abnormal structure of the ZnSe nanowheels composed of teethlike extended patterns on nanoring bases has been successfully synthesized by thermal evaporation method. It is interesting to note that the as-synthesized ZnSe nanowheels are metastable wurtzite phase with the dominant exposed surfaces of ± (2 1- 1- 0) while the stable ZnSe is typically zinc blende phase. A full picture of the growth mechanism of the metastable wurtzite phase ZnSe nanostructures will be proposed from the thermodynamic point of view. Meanwhile, the formation of the nanowheels is also explained by a two-stage mechanism. In the first stage, the base of the nanowheel begins to form by vapor-solid mechanism, while in the second stage, the teethlike extended structures grow through the self-catalyzed growth process. The cathodoluminescence spectrum of ZnSe nanowheel exhibited a band edge transition at about 460 nm and a strong self-activated luminescence at 610 nm. It is important to note that the discussions of the nanostructure thermodynamics and stability can be applied to understand the growth mechanism of other nanostructures which are critical for optimization of the nanostructures. © 2007 American Institute of Physics.published_or_final_versio

1000 nm tunable acousto-optic filter based on photonic crystal fiber

Author name used in this publication: W. JinAuthor name used in this publication: J. Ju2007-2008 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

MicroRNA-143 is a potential tumor suppressor targeting DNA methyltransferases 3a in colorectal cancer

Gastroenterology, 2009, v. 136 n. 5, suppl.1, p. A165, abstract no. 10692009 DDW (Digestive Disease Week) Abstract Supplement , AGA (American Gastroenterological Association) Institute Topic Forum, Oral sessions: Scientific sessions: Microrna and digestive cancers, Oral presentation no. 1069postprin

Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection

Background: We previously showed microRNAs (miRNAs) in plasma are potential biomarkers for colorectal cancer detection. Here, we aimed to develop specific blood-based miRNA assay for breast cancer detection. Methodology/Principal Findings: TaqMan-based miRNA profiling was performed in tumor, adjacent non-tumor, corresponding plasma from breast cancer patients, and plasma from matched healthy controls. All putative markers identified were verified in a training set of breast cancer patients. Selected markers were validated in a case-control cohort of 170 breast cancer patients, 100 controls, and 95 other types of cancers and then blindly validated in an independent set of 70 breast cancer patients and 50 healthy controls. Profiling results showed 8 miRNAs were concordantly up-regulated and 1 miRNA was concordantly down-regulated in both plasma and tumor tissue of breast cancer patients. Of the 8 up-regulated miRNAs, only 3 were significantly elevated (p<0.0001) before surgery and reduced after surgery in the training set. Results from the validation cohort showed that a combination of miR-145 and miR-451 was the best biomarker (p<0.0001) in discriminating breast cancer from healthy controls and all other types of cancers. In the blind validation, these plasma markers yielded Receiver Operating Characteristic (ROC) curve area of 0.931. The positive predictive value was 88% and the negative predictive value was 92%. Altered levels of these miRNAs in plasma have been detected not only in advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was 96%. Conclusions: These results suggested that these circulating miRNAs could be a potential specific biomarker for breast cancer screening. © 2013 Ng et al.published_or_final_versio

A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

published_or_final_versio

Prostaglandin E2 receptor regulates metastasis and stem-cell like properties in triple-negative breast cancer through SCL19A3

Poster Presentation - Tumor and Cell Biology: no. PO188BACKGROUND/PURPOSE: Majority of BRCA1 mutation-associated tumors share pheno-typic similarity to triple-negative breast cancer (TNBC), understanding the biology of TNBC may improve management of these patients. TNBC is associated with increased risk of metastatic disease and poor prognosis. Prostaglandin E (EP) receptors have been associated with tumor metastasis, however, the contribution on cancer stem cell compartment …published_or_final_versio

Late inception of a resiliently oxygenated upper ocean

This is the author accepted manuscript. The final version is available from American Association for the Advancement of Science via the DOI in this record Rising oceanic and atmospheric oxygen levels through time have been crucial to enhanced habitability of surface Earth environments. Few redox proxies can track secular variations in dissolved oxygen concentrations around threshold levels for metazoan survival in the upper ocean. We present an extensive compilation of iodine-to-calcium ratios (I/Ca) in marine carbonates. Our record supports a major rise in the partial pressure of oxygen in the atmosphere at ~400 million years (Ma) ago and reveals a step change in the oxygenation of the upper ocean to relatively sustainable near-modern conditions at ~200 Ma ago. An Earth system model demonstrates that a shift in organic matter remineralization to greater depths, which may have been due to increasing size and biomineralization of eukaryotic plankton, likely drove the I/Ca signals at ~200 Ma ago.NER

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

Copyright \ua9 2023 Massachusetts Medical Society.BACKGROUND: The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear. METHODS: In a pragmatic trial, we randomly assigned, in a 1:1 ratio, infants who were 12 months of age or younger, had been born at a gestational age of at least 29 weeks, and were entering their first RSV season in France, Germany, or the United Kingdom to receive either a single intramuscular injection of nirsevimab or standard care (no intervention) before or during the RSV season. The primary end point was hospitalization for RSV-associated lower respiratory tract infection, defined as hospital admission and an RSV-positive test result. A key secondary end point was very severe RSV-associated lower respiratory tract infection, defined as hospitalization for RSV-associated lower respiratory tract infection with an oxygen saturation of less than 90% and the need for supplemental oxygen. RESULTS: A total of 8058 infants were randomly assigned to receive nirsevimab (4037 infants) or standard care (4021 infants). Eleven infants (0.3%) in the nirsevimab group and 60 (1.5%) in the standard-care group were hospitalized for RSV-associated lower respiratory tract infection, which corresponded to a nirsevimab efficacy of 83.2% (95% confidence interval [CI], 67.8 to 92.0; P&lt;0.001). Very severe RSV-associated lower respiratory tract infection occurred in 5 infants (0.1%) in the nirsevimab group and in 19 (0.5%) in the standard-care group, which represented a nirsevimab efficacy of 75.7% (95% CI, 32.8 to 92.9; P = 0.004). The efficacy of nirsevimab against hospitalization for RSV-associated lower respiratory tract infection was 89.6% (adjusted 95% CI, 58.8 to 98.7; multiplicity-adjusted P&lt;0.001) in France, 74.2% (adjusted 95% CI, 27.9 to 92.5; multiplicity-adjusted P = 0.006) in Germany, and 83.4% (adjusted 95% CI, 34.3 to 97.6; multiplicity-adjusted P = 0.003) in the United Kingdom. Treatment-related adverse events occurred in 86 infants (2.1%) in the nirsevimab group. CONCLUSIONS: Nirsevimab protected infants against hospitalization for RSV-associated lower respiratory tract infection and against very severe RSV-associated lower respiratory tract infection in conditions that approximated real-world settings. (Funded by Sanofi and AstraZeneca; HARMONIE ClinicalTrials.gov number, NCT05437510)